U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details


Last Revision: June 21, 2021.

Estimated reading time: 1 minute

CASRN: 706808-37-9

Drug Levels and Effects

Summary of Use during Lactation

Information from one patient indicates that the drug may be used in nursing mothers; however, more data are needed. Since glycosylated belatacept has a molecular weight of 92,300 Da, it is unlikely to appear in milk. The manufacturer recommends avoiding nursing if belatacept is given. Because the drug's half-life is 8 to 10 days, it may be more than a month after a dose before the drug is absent from breastmilk.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

A mother with a liver transplant was maintained on belatacept 10 mg/kg monthly, slow-release tacrolimus (Envarsus and Veloxis) 2 mg daily, azathioprine 25 mg daily, and prednisone 2.5 mg daily. She breastfed her infant for a year (extent not stated). The infant’s growth and cognitive milestones were normal.[1]

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Azathioprine, Cyclosporine, Tacrolimus


Klintmalm GB, Gunby RT Jr. Successful pregnancy in a liver transplant recipient on belatacept. Liver Transpl. 2020;26:1193–4. [PubMed: 32337853]

Substance Identification

Substance Name


CAS Registry Number


Drug Class

Breast Feeding


Immunosuppressive Agents

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.


Related information

Similar articles in PubMed

  • Review Elotuzumab[Drugs and Lactation Database (...]
    Review Elotuzumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Abatacept[Drugs and Lactation Database (...]
    Review Abatacept
    . Drugs and Lactation Database (LactMed). 2006
  • Review Ipilimumab[Drugs and Lactation Database (...]
    Review Ipilimumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Durvalumab[Drugs and Lactation Database (...]
    Review Durvalumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Etanercept[Drugs and Lactation Database (...]
    Review Etanercept
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...